CAPR vs. CLSD, PRPH, LPTX, EYEN, NRBO, WVE, NUVB, PRAX, PAHC, and STOK
Should you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include Clearside Biomedical (CLSD), ProPhase Labs (PRPH), Leap Therapeutics (LPTX), Eyenovia (EYEN), NeuroBo Pharmaceuticals (NRBO), Wave Life Sciences (WVE), Nuvation Bio (NUVB), Praxis Precision Medicines (PRAX), Phibro Animal Health (PAHC), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical preparations" industry.
Clearside Biomedical (NASDAQ:CLSD) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, community ranking, analyst recommendations, institutional ownership and media sentiment.
Clearside Biomedical received 11 more outperform votes than Capricor Therapeutics when rated by MarketBeat users. Likewise, 67.17% of users gave Clearside Biomedical an outperform vote while only 62.73% of users gave Capricor Therapeutics an outperform vote.
In the previous week, Clearside Biomedical had 2 more articles in the media than Capricor Therapeutics. MarketBeat recorded 5 mentions for Clearside Biomedical and 3 mentions for Capricor Therapeutics. Clearside Biomedical's average media sentiment score of 1.21 beat Capricor Therapeutics' score of 0.75 indicating that Capricor Therapeutics is being referred to more favorably in the news media.
18.8% of Clearside Biomedical shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 9.2% of Clearside Biomedical shares are held by company insiders. Comparatively, 12.0% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Clearside Biomedical has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 4.06, meaning that its stock price is 306% more volatile than the S&P 500.
Capricor Therapeutics has a net margin of -89.72% compared to Capricor Therapeutics' net margin of -413.73%. Capricor Therapeutics' return on equity of 0.00% beat Clearside Biomedical's return on equity.
Capricor Therapeutics has higher revenue and earnings than Clearside Biomedical. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Clearside Biomedical, indicating that it is currently the more affordable of the two stocks.
Clearside Biomedical currently has a consensus price target of $4.50, suggesting a potential upside of 223.74%. Capricor Therapeutics has a consensus price target of $21.75, suggesting a potential upside of 256.56%. Given Clearside Biomedical's higher possible upside, analysts plainly believe Capricor Therapeutics is more favorable than Clearside Biomedical.
Summary
Capricor Therapeutics beats Clearside Biomedical on 9 of the 16 factors compared between the two stocks.
Get Capricor Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Capricor Therapeutics Competitors List
Related Companies and Tools
